Dysfunctional NO metabolism, a hallmark of CAD, impairs vasodilation and contributes to thrombosis, inflammation, and vascular proliferation, exacerbating STEMI progression [10,11]. NOS3 gene polymorphisms, such as allelic variants affecting NO production, further illustrate the genetic basis of CAD [12,13]. The gene discussed is NOS3; the disease is coronary artery disorder.